Prolonged clinical benefit of everolimus therapy in the management of high-grade pancreatic neuroendocrine carcinoma.
about
Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysisDoes the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas?A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma.Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives.The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma.Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea.Impact of everolimus on Japanese patients with advanced pancreatic neuroendocrine neoplasms.
P2860
Q33648996-9BF592EC-0122-48B5-975F-03B2D71D1057Q35681825-C7EED9F6-BA7C-49D8-A46B-534EF3EFB9B5Q36300517-2E32ACC7-C0CC-4984-8645-0ADA926AB91CQ37361194-8CCA4D5F-2154-469D-8F84-6564C81399DFQ38371367-18EDFEFC-8095-4F4D-ACBB-C22F47A29EF9Q38527936-269D5A5E-94AF-498F-9806-70ADA9AE9AB7Q38666243-4F53B96A-3410-48D2-B555-3C013780409EQ46392522-0AD9C451-5BD2-45A9-9BA7-9E9678260D6FQ50201468-F3D8C095-0392-426F-B3BC-0DC45A1DD7F7Q53545250-8C327434-9637-421D-8C79-F65C7835CC8B
P2860
Prolonged clinical benefit of everolimus therapy in the management of high-grade pancreatic neuroendocrine carcinoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Prolonged clinical benefit of ...... atic neuroendocrine carcinoma.
@en
Prolonged clinical benefit of ...... atic neuroendocrine carcinoma.
@nl
type
label
Prolonged clinical benefit of ...... atic neuroendocrine carcinoma.
@en
Prolonged clinical benefit of ...... atic neuroendocrine carcinoma.
@nl
prefLabel
Prolonged clinical benefit of ...... atic neuroendocrine carcinoma.
@en
Prolonged clinical benefit of ...... atic neuroendocrine carcinoma.
@nl
P2093
P2860
P356
P1476
Prolonged clinical benefit of ...... eatic neuroendocrine carcinoma
@en
P2093
Carlos Alvarez
Esther Uriol
José M Viéitez
José P Berros
Marta Izquierdo
Noemi Villanueva
Paula J Fonseca
Quionia Pérez
P2860
P304
P356
10.1159/000354754
P50
P577
2013-08-24T00:00:00Z